Harmony Biosciences Holdings, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 38.59 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.25B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company’s products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Details
| Name | Harmony Biosciences Holdings, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 293 |
| Founded | 2017 |
| Ipo Date | 2020-08-19 |
| Ceo | Jeffrey Dayno |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 24.00 |
| Isin | US4131971040 |
| Cusip | 413197104 |
| Cik | 1802665 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Jeffrey M. Dayno M.D. | President, Chief Executive Officer and Director |
| Jeffrey S. Aronin | Founder and Non-Executive Chairman |
| Dr. Kumar Budur M.D., M.S. | Executive Vice President and Chief Medical and Scientific Officer |
| Andrew Serafin J.D., M.B.A. | Executive Vice President and Chief Strategy Officer |
| Adam Zaeske | Executive Vice President and Chief Commercial Officer |
| Stephen Mollichella | Senior Vice President, Controller and Interim Principal Financial Officer |
| Brennan Doyle | Vice President and Head of Investor Relations |
| Christian Ulrich J.D. | Executive Vice President, General Counsel and Corporate Secretary |
| Tricia Glover | Chief Compliance Officer |
| Audrey Murphy SPHR | Chief Human Resources Officer |
Contact
| Address | 630 West Germantown Pike, Suite 215, Plymouth Meeting, Pennsylvania 19462, United States |
| Phone | 484 539 9800 |
| Website | https://www.harmonybiosciences.com |